Local Covid-19 vaccine final trials may end within 2 months: Harsh Vardhan

The state-run Indian Council of Medical Research (ICMR) and privately-held Bharat Biotech this month started third-stage trials of COVAXIN, in a process that would involve 26,000 volunteers

Harsh Vardhan
"We are in the process of developing our indigenous vaccines, in the process of completing our third-phase trials in the next one or two months," Harsh Vardhan told a web conference on the pandemic
Reuters New Delhi
2 min read Last Updated : Nov 22 2020 | 10:58 PM IST
India's health minister said on Sunday a locally-developed Covid-19 vaccine candidate could complete its final trials in a month or two, raising hopes for a rapid roll-out in a country with the world's second highest number of infections.
 
The state-run Indian Council of Medical Research (ICMR) and privately-held Bharat Biotech this month started third-stage trials of COVAXIN, in a process that would involve 26,000 volunteers. It is the most advanced Indian experimental vaccine.
 
"We are in the process of developing our indigenous vaccines, in the process of completing our third-phase trials in the next one or two months," Harsh Vardhan told a web conference on the pandemic.
 
He reiterated the government's plan was to immunise 200 million to 250 million Indians by July.
 
An ICMR scientist told Reuters earlier this month the vaccine could be launched in February or March, although Bharat Biotech separately told Reuters on Friday that results of the late-stage trials were expected only between March and April.
 
Vardhan, however, said in September the government could opt for emergency vaccine authorisation, particularly for the elderly and people in high-risk workplaces.
 
Indian officials have said they expect to rely on COVAXIN and four other locally-tested candidates to control Covid-19, as they do not expect early access to sufficient quantities of those developed by Pfizer and Moderna.
 
The other experimental vaccines on trial in India are the one being developed by AstraZeneca and Oxford University that is being manufactured by the Serum Institute of India; Russia's Sputnik-V; Zydus Cadila's ZyCoV-D and lastly one that Biological E. Ltd is developing with Baylor College of Medicine and Dynavax Technologies Corp.
 
Serum's CEO said on Friday the AstraZeneca vaccine could be delivered to Indian healthcare workers and the elderly by January.
 
India on Sunday recorded 45,209 new infections, taking the total to 9.09 million, only behind that of the United States.
 
Deaths rose by 501 to 133,227, with Delhi recording the highest number of daily fatalities in the country over the last few days.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineHarsh Vardhan

Next Story